The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome

European Journal of Immunology

Volumn 45, Issue 12, 2015, Pages 3351-3361

  Goyvaerts, Cleo ^a   Broos, Katrijn ^a   Escors, David ^b   Heirman, Carlo ^a   Raes, Geert ^a,c   De Baetselier, Patrick ^a,c   Thielemans, Kris ^a   Breckpot, Karine ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b Atención Primaria Y Promoción de La Salud   (Spain)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Antigen presenting cell; Cancer; IL 12; Immunotherapy; Lentiviral vector; Nanobody; Targeting

Indexed keywords

CANCER VACCINE; DC2.1 DISPLAYING LENTIVIRUS VECTOR; INTERLEUKIN 12; LENTIVIRUS VECTOR; OVALBUMIN; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS DERIVED GLYCOPROTEIN LENTIVIRUS VECTOR; G PROTEIN, VESICULAR STOMATITIS VIRUS; MEMBRANE PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; EMBRYO; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TH1 CELL; TUMOR IMMUNITY; VIRAL TROPISM; ANIMAL; C57BL MOUSE; GENETIC TRANSDUCTION; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; LENTIVIRINAE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HEK293 CELLS; HUMANS; INTERLEUKIN-12; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS;

EID: 84952638475     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201545559     Document Type: Article

References (46)

1. Hoepner, S. and Walker, P. R., Getting by with a little help from the right CD4+ T cells. Oncoimmunology 2013. 2: 10-12.
2. Schijns, V., Tartour, E., Michalek, J., Stathopoulos, A., Dobrovolskiene, N. T. and Strioga, M. M., Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines. Cytotherapy 2013. 16: 427-439.
3. Accolla, R. S., Lombardo, L., Abdallah, R., Raval, G., Forlani, G. and Tosi, G., Boosting the MHC class II-restricted tumor antigen presentation to CD4+ T helper cells: a critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state. Front. Oncol. 2014. 4: 1-9.
4. Church, S. E., Jensen, S. M., Antony, P. A., Restifo, N. P. and Fox, B. A., Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur. J. Immunol. 2014. 44: 69-79.
5. Dullaers, M., Van Meirvenne, S., Heirman, C., Straetman, L., Bonehill, A., Aerts, J. L., Thielemans, K. et al., Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 2006. 13: 630-640.
6. Rowe, H. M., Lopes, L., Ikeda, Y., Bailey, R., Barde, I., Zenke, M., Chain, B. M. et al., Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol. Ther. 2006. 13: 310-319.
7. Escors, D. and Breckpot, K., Lentiviral vectors in gene therapy: their current status and future potential. Arch. Immunol. Ther. Exp. (Warsz). 2010. 58: 107-119.
8. Goyvaerts, C., De Groeve, K., Dingemans, J., Van Lint, S., Robays, L., Heirman, C., Reiser, J. et al., Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther. 2012. 19: 1133-1140.
9. Goyvaerts, C., Dingemans, J., De Groeve, K., Heirman, C., Van Gulck, E., Vanham, G., De Baetselier, P. et al., Targeting of human antigen-presenting cell subsets. J. Virol. 2013. 87: 11304-11308.
10. Goyvaerts, C., Kurt, D. G., Van Lint, S., Heirman, C., Van Ginderachter, J. A., De Baetselier, P., Raes, G. et al., Immunogenicity of targeted lentivectors. Oncotarget 2014. 5: 704-715.
11. Ciré, S., Da Rocha, S., Yao, R., Fisson, S., Buchholz, C. J., Collins, M. K. and Galy, A., Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo. PLoS One 2014. 9: 1-10.
12. Vignali, D. A. A. and Kuchroo, V. K., IL-12 family cytokines: immunological playmakers. Nat. Immunol. 2012. 13: 722-728.
13. Xu, M., Mizoguchi, I., Morishima, N., Chiba, Y., Mizuguchi, J. and Yoshimoto, T., Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin. Dev. Immunol. 2010. 2010: 1-9.
14. Del Vecchio, M., Bajetta, E., Canova, S., Lotze, M. T., Wesa, A., Parmiani, G. and Anichini, A., Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 2007. 13: 4677-4685.
15. Kilinc, M. O., Aulakh, K. S., Nair, R. E., Jones, S. A., Alard, P., Kosiewicz, M. M. and Egilmez, N. K., Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J. Immunol. 2006. 177: 6962-6973.
16. Liechtenstein, T., Perez-Janices, N., Blanco-Luquin, I., Goyvaerts, C., Schwarze, J., Dufait, I., Lanna, A. et al., Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology 2014. 3: 1-16.
17. Iyoda, T., Shimoyama, S., Liu, K., Omatsu, Y., Akiyama, Y., Maeda, Y., Takahara, K. et al., The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 2002. 195: 1289-1302.
18. Rodriguez-Madoz, J. R., Prieto, J. and Smerdou, C., Semliki Forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol. Ther. 2005. 12: 153-163.
19. Yin, X., Wang, N., Wei, X., Xie, G., Li, J. and Liang, H., Interleukin-12 inhibits the survival of human colon cancer stem cells in vitro and their tumor initiating capacity in mice. Cancer Lett. 2012. 322: 92-97.
20. Lasek, W., Zagozdzon, R. and Jakobisiak, M., Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol. Immunother. 2014. 63: 419-435.
21. Wolfl, M., Kuball, J., Ho, W. Y., Nguyen, H., Manley, T. J., Bleakley, M. and Greenberg, P. D., Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007. 110: 201-210.
22. Orange, J. S., Salazar-Mather, T. P., Opal, S. M., Spencer, R. L., Miller, A. H., McEwen, B. S. and Biron, C. A., Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J. Exp. Med. 1995. 181: 901-914.
23. You, C.-X., Shi, M., Liu, Y., Cao, M., Luo, R. and Hermonat, P. L., AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: evidence for IL-12 intracrine activity in DC. Oncoimmunology 2012. 1: 847-855.
24. Zitvogel, L. and Kroemer, G., CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance. Cancer Cell. 2014. 26: 591-593.
25. Ahmed Ali, H. A., Di, J., Mei, W., Zhang, Y.-C., Li, Y., Du, Z.-W. and Zhang, G.-Z., Antitumor activity of lentivirus-mediated interleukin -12 gene modified dendritic cells in human lung cancer in vitro. Asian Pac. J. Cancer Prev. 2014. 15: 611-616.
26. Labbe, A., Nelles, M., Walia, J., Jia, L., Furlonger, C., Nonaka, T., Medin, J. A. et al., IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy. J. Cell. Mol. Med. 2009. 13: 1962-1976.
27. Breckpot, K., Emeagi, P., Dullaers, M., Michiels, A., Heirman, C. and Thielemans, K., Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum. Gene Ther. 2007. 18: 536-546.
28. Tan, P. H., Beutelspacher, S. C., Xue, S.-A., Wang, Y.-H., Mitchell, P., McAlister, J. C., Larkin, D. F. P. et al., Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 2005. 105: 3824-3832.
29. Lim, H. X., Hong, H.-J., Jung, M. Y., Cho, D. and Kim, T. S., Principal role of IL-12p40 in the decreased Th1 and Th17 responses driven by dendritic cells of mice lacking IL-12 and IL-18. Cytokine 2013. 63: 179-186.
30. Suzuki, S., Umezu, Y., Saijo, Y., Satoh, G., Abe, Y., Satoh, K. and Nukiwa, T., Exogenous recombinant human IL-12 augments MHC class I antigen expression on human cancer cells in vitro. Tohoku J. Exp. Med. 1998. 185: 223-226.
31. Tan, C., Dannull, J., Nair, S. K., Ding, E., Tyler, D. S., Pruitt, S. K. and Lee, W. T., Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. J. Surg. Res. 2013. 185: 904-911.
32. Oh, S. and Hwang, E. S., The role of protein modifications of T-bet in cytokine production and differentiation of T helper cells. J. Immunol. Res. 2014. 2014: 1-7.
33. Romee, R., Leong, J. W. and Fehniger, T. A., Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) 2014. 2014: 1-18.
34. Chen, S. H., Pham-Nguyen, K. B., Martinet, O., Huang, Y., Yang, W., Thung, S. N., Chen, L. et al., Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol. Ther. 2000. 2: 39-46.
35. Quetglas, J. I., Dubrot, J., Bezunartea, J., Sanmamed, M. F., Hervas-Stubbs, S., Smerdou, C. and Melero, I., Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol. Ther. 2012. 20: 1664-1675.
36. Zhang, Y., Ma, C. J., Wang, J. M., Ji, X. J., Wu, X. Y., Jia, Z. S., Moorman, J. P. et al., Tim-3 negatively regulates IL-12 expression by monocytes in HCV infection. PLoS One 2011. 6: 1-14.
37. Markiewicz, M. A., Wise, E. L., Buchwald, Z. S., Cheney, E. E., Hansen, T. H., Suri, A., Cemerski, S. et al., IL-12 enhances CTL synapse formation and induces self-reactivity. J. Immunol. 2009. 182: 1351-1361.
38. Melero, I., Duarte, M., Ruiz, J., Sangro, B., Galofré J, Mazzolini, G., Bustos, M. et al., Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther. 1999. 6: 1779-1784.
39. Mendiratta, S. K., Quezada, A., Matar, M., Wang, J., Hebel, H. L., Long, S., Nordstrom, J. L. et al., Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. Gene Ther. 1999. 6: 833-839.
40. Hess, S. D., Egilmez, N. K., Bailey, N., Anderson, T. M., Mathiowitz, E., Bernstein, S. H. and Bankert, R. B., Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J. Immunol. 2003. 170: 400-412.
41. Yang, L., Zaharoff, D. A., Role of chitosan co-formulation in enhancing interleukin-12 delivery and antitumor activity. Biomaterials 2013. 34: 3828-3836.
42. Daenthanasanmak, A., Salguero, G., Borchers, S., Figueiredo, C., Jacobs, R., Sundarasetty, B. S., Schneider, A. et al., Integrase-defective lentiviral vectors encoding cytokines induce differentiation of human dendritic cells and stimulate multivalent immune responses in vitro and in vivo. Vaccine 2012. 30: 5118-5131.
43. Van Meirvenne, S., Straetman, L., Heirman, C., Dullaers, M., De Greef, C., Van Tendeloo, V. and Thielemans, K., Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther. 2002. 9: 787-797.
44. Zhang, X.-Y., Kutner, R. H., Bialkowska, A., Marino, M. P., Klimstra, W. B. and Reiser, J., Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, Vesicular stomatitis virus, or Avian sarcoma/leukosis virus. Retrovirology 2010. 7: 1-15.
45. Brown, B. D., Venneri, M. A., Zingale, A., Sergi Sergi, L. and Naldini, L., Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med. 2006. 12: 585-591.
46. Tuyaerts, S., Michiels, A., Corthals, J., Bonehill, A., Heirman, C., de Greef, C., Noppe, S. M. et al., Induction of influenza matrix protein 1 and melanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther. 2003. 10: 696-706.